Journal of Peking University(Health Sciences) >
Abnormal elevation of growth hormone in patients with pituitary adenoma combined with cirrhosis: A case report
Received date: 2021-10-11
Online published: 2025-04-12
Copyright
The oral glucose growth hormone suppression test is commonly used in the clinical diagnosis of acromegaly, but its results can be influenced by a variety of factors. This case report discusses a patient with a pituitary tumor and concurrent liver cirrhosis, highlighting the complexities in interpreting test results under such conditions. The patient, a 54-year-old male, presented with blurred vision as his primary complaint. Notably, the physical examination revealed no changes in facial features, no enlargement of hands or feet, and no other symptoms typically associated with acromegaly, which might otherwise suggest excessive growth hormone activity. Magnetic Resonance Imaging (MRI) of the pituitary gland indicated that the gland was within normal size parameters, but a small low-intensity lesion mea-suring approximately 3 mm×2 mm identified. This finding was consistent with a pituitary microadenoma. The patient's fasting growth hormone levels were significantly elevated at 8.470 μg/L, compared with the normal range of less than 2.47 μg/L. Conversely, fasting insulin-like growth factor-1 (IGF-1) levels were notably low, recorded at 41 and 52 μg/L, whereas the normal range for a person of his age was between 87 and 234 μg/L. Other pituitary hormones, including those regulating the thyroid, adrenal cortex, and sex hormones, were found to be within normal ranges. Despite this, during the glucose growth hormone suppression test, an abnormal elevation of growth hormone was observed. To investigate further, the patient was administered branched-chain amino acids, and the suppression test was repeated. However, the abnormal elevation of growth hormone persisted, indicating a failure to normalize the response. Given the patient's lack of clinical signs typically associated with elevated growth hormone secretion, the history of liver cirrhosis became a significant consideration. The disparity between elevated growth hormone levels and reduced IGF-1 levels suggested that the pituitary lesion was a non-functional adenoma rather than a source of excess hormone production. Consequently, it was concluded that the abnormal response of growth hormone to the glucose suppression test was likely related to the patient's liver cirrhosis. In addition to chronic liver disease, various other conditions could influence the results of the oral glucose tolerance growth hormone suppression test. According to the literature, factors such as puberty, diabetes, anorexia nervosa, and protein malnutrition could also affect test outcomes. These conditions could cause similar abnormalities in growth hormone dynamics, complicating the diagnosis. Therefore, clinicians must be vigilant and consider these potential influences when interpreting test results.For an accurate diagnosis of acromegaly, it is essential to combine clinical symptoms, detailed medical history, and imaging studies. The presence of conditions like liver cirrhosis should prompt careful interpretation of the test results, ensuring that other contributing factors are not overlooked. This comprehensive approach is crucial to avoid misdiagnosis and to ensure that appropriate treatment strategies are implemented based on a thorough understanding of the patient's overall health status.
Key words: Pituitary neoplasms; Liver cirrhosis; Glucose tolerance test
Yanlei WANG , Min DUAN , Jianzhong XIAO , Wenhui ZHAO . Abnormal elevation of growth hormone in patients with pituitary adenoma combined with cirrhosis: A case report[J]. Journal of Peking University(Health Sciences), 2025 , 57(2) : 400 -402 . DOI: 10.19723/j.issn.1671-167X.2025.02.029
| 1 | 中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36 (9): 751- 760. |
| 2 | Ceccato F , Vedolin CK , Voltan G , et al. Paradoxical GH increase after oral glucose load in subjects with and without acromegaly[J]. J Endocrinol Invest, 2024, 47 (1): 213- 221. |
| 3 | 母义明. 垂体瘤诊治进展[J]. 解放军医学杂志, 2017, 42 (7): 576- 582. |
| 4 | Aldahmani KM , Sreedharan J , Ismail MM , et al. Prevalence and characteristics of sellar masses in the city of Al Ain, United Arab Emirates: 2010 to 2016[J]. Ann Saudi Med, 2020, 40 (2): 105- 112. |
| 5 | Gorbacheva AM , Przhiyalkovskaya EG , Azizyan VN , et al. An ovarian hyperstimulation syndrome caused by gonadotropinoma in a young woman[J]. Probl Endokrinol (Mosk), 2019, 65 (4): 278- 288. |
| 6 | 闵佳, 丁惠国, 闫惠萍, 等. 肝炎后肝硬化患者生长激素: 胰岛素样生长因子轴变化及其临床意义[J]. 中华国际医学杂志, 2002, 2 (4): 311- 313. |
| 7 | 刘哲, 刘永雄, 冯玉泉. 生长激素与肝脏[J]. 中华肝胆外科杂志, 2001, 7 (1): 59- 61. |
| 8 | 钱学敏, 李继强. 生长激素抵抗和肝硬化[J]. 国际消化病杂志, 2001, 21 (2): 97- 100. |
| 9 | Martina V , Tagliabue M , Bruno GA , et al. The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis[J]. Clin Endocrinol (Oxf), 1998, 48 (2): 175- 180. |
| 10 | Atquet V , Alexopoulou O , Maiter D . Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load[J]. Eur J Endocrinol, 2021, 185 (2): 313- 321. |
| 11 | Umahara M , Okada S , Ohshima K , et al. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly[J]. Endocr J, 2003, 50 (5): 643- 650. |
| 12 | Hage M , Chaligne R , Viengchareun S , et al. Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas[J]. J Clin Endocrinol Metab, 2019, 104 (5): 1777- 1787. |
| 13 | Oba-Yamamoto C , Kameda H , Miyoshi H , et al. Acromegaly cases exhibiting increased growth hormone levels during oral glucose loading with preadministration of dipeptidyl peptidase-4 inhibitor[J]. Intern Med, 2021, 60 (15): 2375- 2383. |
| 14 | Hage M , Kamenicky P , Chanson P . Growth hormone response to oral glucose load: From normal to pathological conditions[J]. Neuroendocrinology, 2019, 108 (3): 244- 255. |
/
| 〈 |
|
〉 |